CORAL SPRINGS, Florida, June 10, 2015 /PRNewswire/ --

Clinical Trials and Innovation Therapies continue to have the potential to drive the pharma and biotech sectors for the final six months of 2015 as forecasts point to the potential for another prosperous year.  Cancer new treatments show promise of immuno-oncology therapies as further studies & trials continue to progress.  Biotech Companies in focus today are Regen BioPharma, Inc. (OTC: RGBP), Sanofi SA (NYSE: SNY), Vical Incorporated (NASDAQ: VICL), RXi Pharmaceuticals Corporation (NASDAQ: RXII), Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI) & Neuralstem, Inc. (NYSE: CUR)

Regen BioPharma, Inc. (OTCBB: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to  address  questions  posed by the FDA regarding  Regn BioPharma, Inc.'s planned  Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability  of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.

Read the full RGBP press release at http://www.financialnewsmedia.com/profiles/rgbp.html

"Using the immune system to treat cancer offers great potential in that the immune system destroys tumor cells, but then establishes immunological memory, which constantly patrols the body for rogue cells." Said Dr. Kesari, "Having served as a member of Regen's Scientific Advisory Board,  I am excited to be involved in this collaboration, in which we aim to help expediently address the questions posed by the FDA and allow for clinical entry of dCellVax."    "As a company we have been fortunate to attract collaborators with established track records of bringing drugs from bench to bedside." Said Thomas Ichim, Ph.D, Chief Scientific Officer of Regen BioPharma.  "In addition to being an internationally renowned clinician, having participated in over 50 clinical trials, Dr. Kesari has been the author of over 200 scientific publications and is the inventor on numerous patents and patent applications in the area of oncology and immunology.  This combination of academic and clinical success is ideal for the current collaboration in which we are trying to address issues at the intersection between basic science and applied medicine. This  collaboration will  provide us the benefit of  Dr. Kesari's  years of expertise in oncology drug development and clinical practice."

In other Biotech and Health Care news & happenings:  After the markets closed on Tuesday, an announcement for a new type of cholesterol-lowering drug made by Sanofi SA (NYSE: SNY) and Regeneron Pharmaceuticals should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.  The panel voted 13-3 to approve the drug, Praluent, the first of a new type of LDL-lowering drug known as PCSK9 inhibitors. A second drug in the class, Amgen Inc's Repatha, will be considered by the panel on Wednesday.  Full release at http://finance.yahoo.com/news/fda-panel-backs-sanofi-regeneron-210606705.html

Vical Incorporated (NASDAQ: VICL) announced in late May the completion of enrollment in a Phase 2 trial of its therapeutic cytomegalovirus (CMV) vaccine in solid organ transplant recipients. ASP0113 is an investigational vaccine candidate under development for the prevention of CMV disease and associated complications in transplant recipients. Vical licensed the vaccine, ASP0113, to Astellas Pharma Inc., which is conducting the Phase 2 trial and an ongoing pivotal Phase 3 trial in hematopoietic stem cell transplant recipients.  VICL closed up over 22% at $1.25 on over 4.4Million shares traded by market close on Tuesday.

RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the areas of dermatology and ophthalmology, announced that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi's novel, self-delivering RNAi platform (sd-rxRNA®). The patent, titled "Reduced Size Self-Delivering RNAi Compounds," covers both the composition and methods of use of RXi's self-delivering platform.  The patent, once issued, will be scheduled to expire in 2031.

Biotechnology firms are a small but growing sector of the pharmaceutical industry and two active biotech companies for yesterday were Neuralstem, Inc. (NYSE: CUR) and Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI). 

Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds.  CUR closed up over 19% at $2.35 on Tuesday on over 2.7Million shares traded by the market close. 

Rock Creek Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease, neurologic disorders, and behavioral health.  RCPI closed up over 71% at $3.55 on over 2.7Million shares traded by the market close on Tuesday.

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services.  If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook:  http://www.facebook.com/financialnewsmedia and Twitter:  http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated three thousand four hundred dollars for news coverage of the current press release issued by Regen BioPharma, Inc., Inc. by the company.  FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email: editor@financialnewsmedia.com 
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC